CN102772520A - Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition - Google Patents
Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition Download PDFInfo
- Publication number
- CN102772520A CN102772520A CN2012102926532A CN201210292653A CN102772520A CN 102772520 A CN102772520 A CN 102772520A CN 2012102926532 A CN2012102926532 A CN 2012102926532A CN 201210292653 A CN201210292653 A CN 201210292653A CN 102772520 A CN102772520 A CN 102772520A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- water
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 143
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 230000003405 preventing effect Effects 0.000 title abstract description 5
- 208000031462 Bovine Mastitis Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 46
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 169
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 61
- 239000007788 liquid Substances 0.000 claims description 34
- 208000004396 mastitis Diseases 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 26
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 241000628997 Flos Species 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 10
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical group CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 10
- 239000012982 microporous membrane Substances 0.000 claims description 10
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 229940056211 paraffin Drugs 0.000 claims description 10
- 239000012188 paraffin wax Substances 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 229960004274 stearic acid Drugs 0.000 claims description 10
- 229940099259 vaseline Drugs 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 241000581682 Sanguisorba Species 0.000 claims description 2
- 241000001522 Terminalia chebula Species 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 241000405217 Viola <butterfly> Species 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 15
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 244000173853 Sanguisorba officinalis Species 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 235000015489 Emblica officinalis Nutrition 0.000 abstract 1
- 244000277583 Terminalia catappa Species 0.000 abstract 1
- 235000011517 Terminalia chebula Nutrition 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000003938 response to stress Effects 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 44
- 239000000243 solution Substances 0.000 description 35
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 20
- 210000000481 breast Anatomy 0.000 description 19
- 235000013336 milk Nutrition 0.000 description 19
- 210000004080 milk Anatomy 0.000 description 19
- 239000008267 milk Substances 0.000 description 19
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 238000004321 preservation Methods 0.000 description 16
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 229960001699 ofloxacin Drugs 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 11
- 229960004755 ceftriaxone Drugs 0.000 description 11
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 11
- 229960000740 enrofloxacin Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 235000019371 penicillin G benzathine Nutrition 0.000 description 9
- 229940056360 penicillin g Drugs 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 238000004064 recycling Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 7
- 229960003405 ciprofloxacin Drugs 0.000 description 7
- 229960005287 lincomycin Drugs 0.000 description 7
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229960003022 amoxicillin Drugs 0.000 description 5
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 5
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229960004682 cefoperazone Drugs 0.000 description 4
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960000484 ceftazidime Drugs 0.000 description 3
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 3
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241001124076 Aphididae Species 0.000 description 2
- 241000974485 Aricia shasta Species 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- 241000037803 Coptis deltoidea Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 241001534869 Terminalia Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000721570 Melaphis Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013273 agar disk-diffusion method Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000006160 differential media Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009654 indole test Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing or treating bovine mastitis and a preparation method of the composition. The traditional Chinese medicine composition comprises the following bulk drugs in parts by weight: 20-40 parts of safflower, 3-18 parts of sanguisorba officinalis, 3-18 parts of gallnut, 3-18 parts of myrobalan, 10-25 parts of rhizoma coptidis and 3-18 parts of radix bupleuri. The traditional Chinese medicine composition has the pharmacological efficacies of clearing away heat and toxic materials, diminishing swelling, removing stasis and enhancing immunity of a human body, can be prepared into transdermal agents, is convenient to use, has no toxic or side effect and stress response, is safe and effective, has no drug resistance, and is low in cost. The components of the composition can directly and rapidly reach the focus. Proven by clinic effect viewing test results, the traditional Chinese medicine composition disclosed by the invention is rapid in taking effect on bovine mastitis, definite in curative effect, and has no toxic or side effect, and is good in safety.
Description
Technical field
The present invention relates to a kind of medicine of treating the cow breast disease; Relate in particular to the Chinese medicine composition of a kind of prevention or treatment mammitis of cow; The invention still further relates to the various pharmaceutical preparatioies that are prepared from this Chinese medicine composition, the invention belongs to the treatment by Chinese herbs field of mammitis of cow.
Background technology
Mammitis of cow be the dairy sickness rate the highest, cause one of disease that economic loss is the most serious.Have or not the naked eyes visible change according to breast and milk, mammitis of cow is divided into two types of clinic mastitis and latent mammitises.Latent mammitis does not have a macroscopic variation in appearance milch cow and breast thereof; The sick cattle that suffers from latent mammitis; Protein content descends in its milk, bacterial content raises, milk composition changes, and causes the quality of sweet milk to descend, and has reduced its nutritive value; In addition, the residual antibiotic of pathogenic microorganism in the milk and western medicine causes a large amount of milk to be abandoned.
At present; China's bovine subclinical mastitis common antibiotics treatment, majority takes the mode of drug combination to give broad-spectrum antibiotic, causes pathogen that the drug resistance of antibacterials is strengthened; Treatment cycle prolongation, dosage increase usually occur, serious appearance is failed to respond to any medical treatment and milch cow is eliminated situation.The increase of administering drug combinations and dosage causes the antibiotics residue problem serious day by day.
Chinese medicine has the effect of heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, and Chinese medicine also can strengthen the animal body immunologic function simultaneously, and is difficult for producing drug resistance.So the treatment by Chinese herbs mastitis is a development trend from now on.At present general administered through oral administration of Chinese medicine or intravenous administration; Have for mastitis treatment that drug effect is low, the shortcoming of therapeutic effect difference; If can directly can improve greatly, so study the optimum selection that the pure Chinese medicine preparation capable of permeating skin of external topical administration is treatment to mastitis in breast topical effect.
Summary of the invention
Technical problem underlying to be solved by this invention provides the Chinese medicine composition of a kind of evident in efficacy, the prevention that has no side effect or treatment mammitis of cow;
Technical problem underlying to be solved by this invention realizes through following technical scheme:
The Chinese medicine composition of a kind of prevention or treatment mammitis of cow comprises that following bulk drugs processes: Flos Carthami 20-40 part, Radix Sanguisorbae 3-18 part, Galla Chinensis 3-18 part, Fructus Chebulae 3-18 part, Rhizoma Coptidis 10-25 part and Radix Bupleuri 3-18 part; The present invention finds through a large amount of pharmacodynamics tests, when containing the Herba Violae of 5-20 weight portion in this Chinese medicine composition, can play better prevention or therapeutical effect for mammitis of cow.
The weight portion of each crude drug is preferably: Flos Carthami 20-25 part, Radix Sanguisorbae 5-10 part, Galla Chinensis 5-10 part, Fructus Chebulae 5-10 part, Rhizoma Coptidis 15-20 part, Radix Bupleuri 5-10 part; Wherein, when this Chinese medicine composition contains the Herba Violae of 10-15 weight portion, can play better prevention or therapeutical effect for mammitis of cow.
Preferred, the weight portion of each crude drug is: 22 parts on Flos Carthami, 8 parts of Radix Sanguisorbaes, 8 parts of Galla Chinensiss, 8 parts of Fructus Chebulaes, 18 parts of Rhizoma Coptidis, 8 parts of Radix Bupleuri; Wherein, when this Chinese medicine composition contains the Herba Violae of 12 weight portions, can play better prevention or therapeutical effect for mammitis of cow.
Chinese medicine composition of the present invention is under Chinese medical theory instructs; According to the achievement in research of modern Chinese medicine pharmacy to the mammitis of cow treatment; In conjunction with inventor's clinical practice experience for many years; Filter out eliminating stasis to stop pain, heat-clearing and toxic substances removing, removing heat from blood repercussive crude drug,, form according to certain weight prescription according to the theory of Chinese medical science prescription.
Flos Carthami: formal name used at school Carthamus tinctorius L. is the tubular corolla of feverfew Flos Carthami Carthamus tinctorius L..Warm in nature, acrid in the mouth; Invigorate blood circulation latus rectum, eliminating stasis to stop pain.Be used for that amenorrhea, dysmenorrhea, lochia are not all right, lump in the abdomen mass in the abdomen, traumatic injury.
Radix Sanguisorbae: formal name used at school: Radix Sanguisorbae is the plant of Rosaceae burnet.Property of medicine picric acid; Cold; Nontoxic, return liver, lung, kidney, large intestine channel.Effect: cooling blood for hemostasis, heat-clearing and toxic substances removing, skin ulcer is held back in detumescence.
Galla Chinensis: latin name: Galla chinensi; Have another name called hundred worm storehouses, Mass Galla chinesis et camelliae Fermentata, gall; For the Chinese Nut-gall aphid of Homoptera aphid section or the female worm of melaphis peitan Tsai et Tang parasitize Anacardiaceae plant " Fructus rhois chinensis " and belong to tender leaf or the petiole of other plant together; Stab and generate a kind of cryptomere consor thing insect gall, gained after baking is doubly dry.Meridian distribution of property and flavor: sour in the mouth is puckery, cold in nature.Return lung, large intestine, kidney channel.Effect: astringe the lung; Hidroschesis; Astringing intestine to stop diarrhea; Controlling nocturnal emission with astringent drugs; Hemostasis; Detoxifcation.
Fructus Chebulae: another name: chebule, scold multitude, scold pears, son with the wind; English name: Medicine Terminalia Fruit, Fruit of medicine Terminalia.Bitter in the mouth; Acid; Puckery; Property is put down.Effect: astringe the lung; Astringing intestine to stop diarrhea; The therapeutic method to keep the adverse QI flowing downwards; Sore-throat relieving.
Rhizoma Coptidis: be the dry rhizome of cohosh Rhizoma Coptidis (Coptis chinensis Franch.), Coptis deltoidea C.Y.Cheng et Hsiao (Coptis deltoidea C.Y.Cheng et Hsiao) and Coptis Teeta Wall (Coptisteeta Wall.).Meridian distribution of property and flavor: hardship, cold, nontoxic.GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel.Function cures mainly: heat clearing and damp drying, eliminating fire and detoxication.
Radix Bupleuri: cold nature, bitter in the mouth, suffering, return Liver Channel, gallbladder meridian.Function: expelling pathogenic factors from the exterior expels the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, elevate a turnable ladder yang-energy.
Herba Violae: formal name used at school: Purplef lower Violet.Another name: Herba violae patrinii, light lobe common violet.The property bitter, hot, cold, nontoxic; GUIXIN, Liver Channel.Function cures mainly: heat-clearing and toxic substances removing, removing heat from blood detumescence.Traumatic injury, carbuncle etc. are controlled in external application.
The used various crude drug of the present invention all can be bought from pharmacy and obtain, and its specification meets country or industry standard gets final product.
Chinese medicine composition of the present invention can be prepared into any acceptable clinically suitable formulations by this area conventional formulation method; For example; Can in the active component of medicine of the present invention, add preparation during different dosage form required various adjuvants (for example disintegrating agent, lubricant, adhesive, transdermal enhancer etc.) be prepared into any suitable clinical preparation with the method for Chinese medicinal of routine, for example can be various external preparation, oral formulations or ejection preparation; Wherein, described external preparation is preferably transdermal agent, unguentum, cataplasma etc., most preferably is transdermal agent; Described oral formulations is preferably powder or decoction etc.
Preferably, a kind of method for preparing above-mentioned Chinese medicine composition, this method may further comprise the steps:
(1) takes by weighing each crude drug by said weight portion;
(2) each crude drug is obtained Chinese medicine extraction liquid with water extraction;
(3) Chinese medicine extraction liquid is mixed with triethanolamine obtain water, add transdermal enhancer again after water and oil phase are mixed, obtain transdermal agent.
Wherein, the method for preparing of described Chinese medicine extraction liquid can prepare with reference to following method:
(a) each crude drug is obtained extracting solution with water extraction; Extracting solution is concentrated, filters;
(b) filtrating adds ethanol, and alcohol deposit fluid is centrifugal, gets supernatant; Supernatant vapors away and adds ethanol again behind the ethanol and carry out precipitate with ethanol, and alcohol deposit fluid is filtered, and filtered solution vapors away ethanol and adds distilled water again, uses filtering with microporous membrane, obtains Chinese medicine extraction liquid.
Wherein, described transdermal enhancer can be an azone, 1,2-propylene glycol, dimethyl sulfoxide, acetylated monoglyceride etc.
Described oil phase comprises stearic acid, glyceryl monostearate, vaseline or paraffin etc.;
The present invention also provides a kind of method for preparing above-mentioned Chinese medicine composition, and this method may further comprise the steps:
(1) takes by weighing each crude drug by said weight portion;
(2) with each crude drug water or ethanol extraction, filter, add required adjuvant or the excipient of preparations shaping, be prepared into decoction or powder.
Chinese medicine composition of the present invention has the effect of heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, enhancing human body immunity function; Can it be prepared into transdermal agent, ingredient can arrive disease sites directly, rapidly, and is easy to use; Have no side effect and stress safe and effective, no Drug resistance, with low cost.The clinical observation on the therapeutic effect result of the test confirms that Chinese medicine composition of the present invention has no side effect for mammitis of cow instant effect, determined curative effect, and safety is good.
Method for using and consumption: the dosage of Chinese medicine composition of the present invention depends on concrete dosage form.As guidance: for transdermal agent, its method for using is following: cleans the ill breast of disease cattle district with warm water before the medication, after clean towel; The transdermal agent 20-30mL with Chinese medicine composition preparation of the present invention is smeared in each breast district; Smear general massage, 2 times/d on one side; 15-20min/ time, 5d is 1 course of treatment.
The specific embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage of the present invention and characteristics will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment with form or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall in protection scope of the present invention the details of technical scheme of the present invention.
The preparation of embodiment 1 transdermal agent
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 22, Radix Sanguisorbae 8, Galla Chinensis 8, the Fructus Chebulae 8, Rhizoma Coptidis 18, Radix Bupleuri 8;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 4 hours, decocted 1 hour, collect decoction liquor, add 500mL water then and decocted for the second time 30 minutes, collect decoction liquor, add 500mL water again and decocted for the third time 30 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 2 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 20, Radix Sanguisorbae 3, Galla Chinensis 3, the Fructus Chebulae 3, Rhizoma Coptidis 10, Radix Bupleuri 3;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 2 hours, decocted 1 hour, collect decoction liquor, add 500mL water then and decocted for the second time 30 minutes, collect decoction liquor, add 500mL water again and decocted for the third time 30 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 3 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 40, Radix Sanguisorbae 18, Galla Chinensis 18, the Fructus Chebulae 18, Rhizoma Coptidis 25, Radix Bupleuri 18;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 5 hours, decocted 1.5 hours, collect decoction liquor, add 500mL water then and decocted for the second time 40 minutes, collect decoction liquor, add 500mL water again and fried in shallow oil for the third time 40 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 36 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 36 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30mi n;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 4 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 20, Radix Sanguisorbae 5, Galla Chinensis 5, the Fructus Chebulae 5, Rhizoma Coptidis 15, Radix Bupleuri 5, Herba Violae 10;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 3 hours, decocted 1 hour, collect decoction liquor, add 500mL water then and decocted for the second time 30 minutes, collect decoction liquor, add 500mL water again and decocted for the third time 30 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24 hours, centrifugal 5 minutes of 3000r/mi n gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 5 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 25, Radix Sanguisorbae 10, Galla Chinensis 10, the Fructus Chebulae 10, Rhizoma Coptidis 20, Radix Bupleuri 10, Herba Violae 15;
2, each crude drug is mixed, mixture is added water 1000mL, behind the immersion 4h, decocted 1 hour, collect decoction liquor, add 500mL water then and decoct 40min for the second time, collect decoction liquor, add 500mL water again and decoct 40min for the third time, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24h, the centrifugal 5min of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24h, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 6 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 22, Radix Sanguisorbae 8, Galla Chinensis 8, the Fructus Chebulae 8, Rhizoma Coptidis 18, Radix Bupleuri 8, Herba Violae 12;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 4 hours, decocted 1 hour, collect decoction liquor, add 500mL water then and decocted for the second time 30 minutes, collect decoction liquor, add 500mL water again and decocted for the third time 30 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 7 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 20, Radix Sanguisorbae 3, Galla Chinensis 3, the Fructus Chebulae 3, Rhizoma Coptidis 10, Radix Bupleuri 3, Herba Violae 5;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 2 hours, decocted 1 hour, collect decoction liquor, add 500mL water then and decocted for the second time 30 minutes, collect decoction liquor, add 500mL water again and decocted for the third time 30 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 24 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 24 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The preparation of embodiment 8 transdermal agents
1, by said weight take by weighing each crude drug (unit: g): Flos Carthami 40, Radix Sanguisorbae 18, Galla Chinensis 18, the Fructus Chebulae 18, Rhizoma Coptidis 25, Radix Bupleuri 18, Herba Violae 20;
2, each crude drug is mixed, mixture is added water 1000mL, soak after 5 hours, decocted 1.5 hours, collect decoction liquor, add 500mL water then and decocted for the second time 40 minutes, collect decoction liquor, add 500mL water again and fried in shallow oil for the third time 40 minutes, collect decoction liquor; The backflow that condensing and recycling distills out in the time of each the decoction merges above-mentioned three decoction liquor and backflow, and 70 ℃ of water-baths are concentrated into 150mL and filter to such an extent that filtrate; It is 95% ethanol that filtrating adds concentration, makes concentration of alcohol reach 60%, gets alcohol deposit fluid after fully stirring, and alcohol deposit fluid is placed 4 ℃ of refrigerators; Cold preservation 36 hours, centrifugal 5 minutes of 3000r/min gets 70 ℃ of water-baths of supernatant, and volatilization goes to add concentration 95% ethanol again behind the ethanol; Make concentration of alcohol reach 80%, again alcohol deposit fluid placed 4 ℃ of refrigerators, cold preservation 36 hours, filter paper filter filtered solution; 70 ℃ of water-baths of filtered solution, ethanol is removed in volatilization, and filtered solution adds distilled water to 100mL; Making solution contain the crude drug amount is 1g/mL, must filtrate with 0.25 micron filtering with microporous membrane, and filtrating obtains Chinese medicine extraction liquid at 121 ℃ of following steam sterilization 30min;
The Chinese medicine extraction liquid for preparing mixed with triethanolamine obtain water; With water with add transdermal agent (azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride) again after oil phase (stearic acid, glyceryl monostearate, vaseline or paraffin) mixes, obtain the Chinese medicine transdermal agent.
The test of Test Example 1 bovine subclinical mastitis separation and Identification of Pathogens
1, test material and method
1.1 test reagent and medicine
The Fossmatic of Denmark FOX company 5000 serial somatic cell fast measuring appearance, dairy industry group in Wanda Mountain provides.
Nutrient agar, Mai Kangkai culture medium, triple sugariron culture medium, the U.S. blue culture medium of Yin Hong, nutrient broth, MH meat soup etc. are available from Shanghai uncle difficult to understand star bio tech ltd.
The biochemical pipe of trace: antibacterials such as hydrogen sulfide, mannitol, sucrose, 0.1% U.S. blue Lac Bovis seu Bubali, sorbitol, gelatin, carbamide, arabinose, 6.5% high salt meat soup, Esculin, lactose, 40% bile broth trace biochemical reaction pipe, available from sky, Hangzhou and microorganism reagent company limited.Lot number: 20090615.
The antibiotics drug sensitive test paper: benzylpenicillin, amoxicillin, ceftazidime, cefazolin sodium, ceftriaxone, cefoperazone, erythromycin, chloromycetin, lincomycin, gentamycin, ciprofloxacin, enrofloxacin, ofloxacin, doxycycline etc., all purchase the Temple of Heaven medicine biotechnology development company in Beijing.Lot number: 0909181.
1.2 test method
Get the milk appearance of aseptic collection and inoculate nutrient agar, rabbit blood culture-medium and broth medium, cultivate 24h for 37 ℃, do not cultivate 1-3d growing the culture medium continuation slowly of bacterium or bacteria growing.Growth such as the shape of observed and recorded antibacterial, size, edge, surface texture, protuberance degree, color, transparency, hardness, haemolysis performance.The sterile working hooks up single bacterium colony, Gram, microscopy.Change and the microscopy result according to clinical data, breast appearance, adopt different differential medium and cultural method to differentiate.
1.2.1 the evaluation of pathogen
1.2.1.1 Gram
⑴ smear is made
The pathogenic bacterium of suspecting on the culture medium after cultivating are put at the microscope slide middle section after connecing the collarium picking, and it is one after another drop of on bacterium colony to get normal saline, evenly is coated with connecing collarium, and smear is fixed through Alcohol Flame, then smear is dyeed.
⑵ dying operation step
1. drip reagent 1 (ammonium oxalate crystal violet dye liquor) in the dry FX of smear, first stain dyeing 1mi n uses distilled water flushing then.
2. after dripping reagent 2 (iodine liquid dye liquor) mordant effect 1min, use distilled water flushing then, inhale the branch that anhydrates with filter paper.
3. drip reagent 3 depigmenting agents (95% ethanol depigmenting agent), should shake slide frequently this moment, and till no purple came off, decolouring 30s cleaned with distilled water, and current can not be too big.
4. drip after reagent 4 (luxuriant red colouring agent) redyes dyeing 30s, distilled water cleans, and waits to do microscopy.
⑶ result judges:
Gram positive bacteria is a purple, and gram negative bacteria is red.
Microscopy preliminary judgement as a result is divided into gram-positive cocci and bacillus, Gram-negative coccus and bacillus.
1.2.1.2 the biochemical identification of pathogen
Antibacterial to pure culture carries out biochemical test inspections such as hemolytic test, various sugar fermentating test (glucose, lactose, maltose, mannitol culture medium), hydrogen peroxide test, triple sugar iron test, 6.5%NaCl test, indole test, hydrogen sulfide production test, Esculin test, hippuric acid test, M.R test, motoricity test.
1.2.1.3 the animal experiment of pathogen
Get the liquid culture abdominal cavity of pathogen and only inoculate white mice 0.5mL/.Every kind of antibacterial is established 3 and repeats a white mice and a matched group (abdominal cavity inoculation 0.5mL 0.9%NaCl), the death condition of white mice in observation of inoculation back and the statistic record 24-48h, and the internal organs of getting firm dead white mice carry out the test of antibacterial isolation identification.
1.2.2 antibiotics drug sensitive test
Measure the sensitivity of the antibiotics class medicine of the bacterial strain that isolation identification goes out with agar disk diffusion method (K-B method).Be inoculated in the LB fluid medium after getting the antibacterial pure culture; 10h is cultivated in 37 ℃ of concussions, draws an amount of bacterium liquid (about 108CFU/mL) with the cotton swab after the sterilization, evenly coats the MH agar plate surface; Branch is evenly placed the various antibiotics drug sensitive test papers of choosing; Behind 24h, with the diameter of slide gauge vertical survey inhibition zone, result's (according to Products Show standard determination) measured in record.
2, result of the test
2.1 bovine subclinical mastitis pathogen isolation identification result sees table 1.
Table 1 bovine subclinical mastitis separation and Identification of Pathogens result
2.2 antibiotic medicine sensitivity tests result
Staphylococcus aureus has tangible resistance to cefoperazone, ceftriaxone, ofloxacin, ciprofloxacin, enrofloxacin sensitivity height to benzylpenicillin, lincomycin, amikacin.
Staphylococcus saprophyticus has tangible resistance to ceftriaxone, ofloxacin, ciprofloxacin, enrofloxacin sensitivity height to benzylpenicillin, streptomycin, amoxicillin.
Staphylococcus epidermidis has tangible resistance to ceftriaxone, enrofloxacin, ofloxacin sensitivity height to benzylpenicillin, streptomycin, gentamycin.
Streptococcus dysgalactiae has tangible resistance to ceftriaxone, enrofloxacin, ofloxacin sensitivity height to benzylpenicillin, gentamycin, streptomycin.
Streptococcus agalactiae has obvious resistance to ceftriaxone, enrofloxacin, ciprofloxacin, ofloxacin sensitivity height to benzylpenicillin, streptomycin, doxycycline.
Streptococcus uberis has tangible resistance to ceftriaxone, enrofloxacin, ofloxacin, ciprofloxacin sensitivity height to penicillin, gentamycin, streptomycin, lincomycin, amoxicillin.
Escherichia coli has obvious resistance to ceftriaxone, cefoperazone, ceftazidime, enrofloxacin, ciprofloxacin, ofloxacin, gentamycin sensitivity height to benzylpenicillin, lincomycin, streptomycin.
Corynebacterium has tangible resistance to ceftriaxone, enrofloxacin, ofloxacin sensitivity height to benzylpenicillin, streptomycin, lincomycin, amoxicillin, doxycycline.
Salmonella has tangible resistance to ceftriaxone, cefoperazone, enrofloxacin, ofloxacin sensitivity height to penicillin, lincomycin, streptomycin amoxicillin.
Bacillus cercus has tangible resistance to ceftriaxone, ceftazidime, enrofloxacin, ofloxacin, ciprofloxacin sensitivity height to amikacin, benzylpenicillin, doxycycline, lincomycin.
Test Example 2 Chinese medicine composition vitro antibacterial activity tests of the present invention
1, test material
1.1 supply the reagent thing: the Chinese medicine extraction liquid that embodiment of the invention 1-8 is prepared;
1.2 the preparation of antibacterial bacterium liquid: the main pathogenic bacterium staphylococcus aureus, escherichia coli, streptococcus dysgalactiae of choosing mammitis of cow picking microbionation successively cultivated 12h for 37 ℃ in the test tube of 5mL MH meat soup.Get 100 these culture fluid of μ L and join in the 2mL MH meat soup, cultivate 12h for 37 ℃, it is an amount of to get bacterium liquid, with 3-5mL normal saline corrected concentrations to 0.5 Maxwell standard, subsequent use.Bacterium liquid after the correction should be inoculated in 15min.
2, bacteriostatic test method
Bacteriostatic test adopts in vitro 2 times of dilution methods of medicinal liquid and combines agar slant to cultivate and carries out; Get 10 in test tube, number consecutively is also arranged, and adds sterilization broth bouillon 2mL in every pipe; Adding concentration then in the 1st pipe is that 1g/mL supplies reagent thing 2mL; Draw 2mL behind the mixing and add in the 2nd pipe, proceed to the 9th pipe successively and dilute, discard 2mL in the 9th pipe.Not adding in the 10th pipe supplies the reagent thing as the antibacterial matched group.By after forward in the above-mentioned test organisms liquid 0.1mL that in vitro adds, place 37 ℃ of calorstats to cultivate 24h.Observe bacterial growth situation in vitro.
The result judges: through cultivate the back as if 1-9 manage contain the highly diluted multiple of medicinal liquid contain the minimum inhibitory concentration (MIC) of concentration as this bacterium.Then above-mentioned 1-9 pipe culture is inoculated in inoculating loop and cultivates 24h on the agar slant again, observe and have or not colony growth, the culture medium drug level that is no more than 5 with clump count is as the minimum bactericidal concentration (MBC) of this prescription, and test repeating 2 times.
3, result of the test
Supplying external antibacterial main mensuration escherichia coli MIC of reagent thing (Chinese medicine extraction liquid) and MBC is 62.5mg/mL, and staphylococcus aureus MIC and MBC are 31.2mg/mL, and streptococcus dysgalactiae MIC and MBC are 31.2mg/mL.
The clinical observation on the therapeutic effect test of Test Example 3 traditional Chinese medicine composition for treating mammitis of cow of the present invention
Choosing of 1 ill milch cow
Select 3 medium-and-large-sized cattle farms in the Harbin City; Cattle farm breeding milk cow kind is a holstein cow; In the 1-12 month in 2009, in the cattle farm of selecting, remove the sick cattle of clinic mastitis, carried out milk somatic cell counting to observing the normal healthy milch cow lactation period in every month.With somatic number 15 * 10
5-150 * 10
5Individual/mL latent mammitis milch cow is classified treatment target as.Be divided into three groups at random, every group 12 cow head: Chinese medicine transdermal agent treatment group (promptly supply examination drug group), ofloxacin group, massage matched group merely.
Table 1 latent mammitis detection method and criterion
2, supply the reagent thing: the Chinese medicine transdermal agent that embodiment of the invention 1-8 is prepared.
3, therapeutic scheme
Choose milk somatic cell count detection 15 * 10
5Individual/mL-150 * 10
5Individual/mL suffers from cattle.For fear of the stress of administration, supply reagent thing (Chinese medicine transdermal agent of the present invention) treatment group after milch cow is milked end, cleans the corresponding ill breast of disease cattle district with warm water before the medication; After drying with dry towel, smear and supply reagent thing (Chinese medicine compound transdermal agent) 20-30mL in each breast district, Yi Bian smear; General massage; 2 times/d, 15-20min/ time, 5d is 1 course of treatment; Ofloxacin group is after milking, and with ofloxacin injection 50mL intramuscular injection, every day 2 times, 5d is 1 course of treatment; But 2 courses of treatment of the case continuous use that is in a bad way, observe therapeutic effect.
Simple massage group milk at every turn finish after, simple massage cream district 15-20min.
4, curative effect determinate standard
After treating 1-2 the course of treatment, judge according to the change of milk production of cow and milk quality.
Cure: the milk perusal is normal to recover with milk yield, spiritual, appetite is normal.Milk somatic cell count detection, Lac Bovis seu Bubali somatic cell number is reduced to 5 * 10
5Individual/below the mL.
Effectively: the milk perusal is normal to recover with milk production of cow on a small quantity, and refreshing essence, appetite are normal.Milk somatic cell count detection, Lac Bovis seu Bubali somatic cell number decreases before test, but still is higher than 5 * 10
5Individual/mL.
5, clinical observation result
Chinese medicine transdermal agent of the present invention is used for clinical therapeutic effect and sees table 2.Chinese medicine transdermal agent treatment group is after 1-2 the course of treatment, and what cure fully is 13 breast districts of 12 cow heads, and breast district cure rate is 81.25%; Breast district significant figure is 14, and breast district effective percentage is 87.50%, does not cure the case clinical symptoms and obviously alleviates.What cure fully the course of treatment is 11 of 12 cow heads breast districts to the ofloxacin group case at 1, and breast district cure rate is 78.57%; Breast district significant figure is 12, and breast district effective percentage is 85.71%.Simple massage group case cure rate is lower, and breast district cure rate is 16.67%; Breast district significant figure is 5, and breast district effective percentage is 41.67%.
The clinical observation on the therapeutic effect result of the test of table 2 traditional Chinese medicine composition for treating mammitis of cow of the present invention
From table 2, can find out, the cure rate and the effective percentage difference of Chinese medicine transdermal agent group of the present invention and ofloxacin group not obvious (P＞0.05), the cure rate of Chinese medicine transdermal agent group of the present invention and massage matched group and effective percentage difference is (P＜0.01) extremely significantly.
In addition, the prepared Chinese medicine transdermal agent of embodiment of the invention 6-8 will exceed the about 7-8 of Chinese medicine transdermal agent percentage point of embodiment 1-5 on the whole for the cure rate of the stealthy mastitis of milch cow.
Clinical observation on the therapeutic effect is the result show, Chinese medicine composition of the present invention is the Chinese prescription of effectively treating latent mammitis clinically, and clinical observation do not see any toxic and side effects, and is clinical safe in utilization.
6, apply test
Adopt Chinese medicine transdermal agent of the present invention to treat to the sick cattle that suffers from latent mammitis, cure over thousands of cow head, cure rate reaches more than 90%.
Claims (10)
1. a Chinese medicine composition that prevents or treat mammitis of cow comprises that each crude drug of following weight portion is formed: Flos Carthami 20-40 part, Radix Sanguisorbae 3-18 part, Galla Chinensis 3-18 part, Fructus Chebulae 3-18 part, Rhizoma Coptidis 10-25 part and Radix Bupleuri 3-18 part.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that the weight portion of each crude drug is: Flos Carthami 20-25 part, Radix Sanguisorbae 5-10 part, Galla Chinensis 5-10 part, Fructus Chebulae 5-10 part, Rhizoma Coptidis 15-20 part, Radix Bupleuri 5-10 part, Herba Violae 10-15 part.
3. according to the described Chinese medicine composition of claim 2, it is characterized in that the weight portion of each crude drug is: 22 parts on Flos Carthami, 8 parts of Radix Sanguisorbaes, 8 parts of Galla Chinensiss, 8 parts of Fructus Chebulaes, 18 parts of Rhizoma Coptidis, 8 parts of Radix Bupleuri, 12 parts of Herba Violaes.
4. according to the described Chinese medicine composition of claim 1, it is characterized in that: the Herba Violae that contains the 5-20 weight portion.
5. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that: it is prepared into any acceptable clinically preparation; Preferably, described preparation comprises external preparation, oral formulations or ejection preparation.
6. according to the described Chinese medicine composition of claim 5, it is characterized in that: described external preparation comprises transdermal agent, unguentum or cataplasma; Described oral formulations is powder or decoction.
7. method for preparing any one said Chinese medicine composition of claim 1-3, this method may further comprise the steps:
(1) takes by weighing each crude drug by said weight portion; (2) each crude drug is obtained Chinese medicine extraction liquid with water extraction; (3) Chinese medicine extraction liquid is mixed with triethanolamine obtain water, add transdermal enhancer again after water and oil phase are mixed, obtain transdermal agent.
8. according to the described method of claim 7, it is characterized in that the method for preparing of described Chinese medicine extraction liquid comprises: (a) each crude drug is obtained extracting solution with water extraction; Extracting solution is concentrated, filters; (b) filtrating adds ethanol, and alcohol deposit fluid is centrifugal, gets supernatant; Supernatant vapors away and adds ethanol again behind the ethanol and carry out precipitate with ethanol, and alcohol deposit fluid is filtered, and filtered solution vapors away ethanol and adds distilled water again, uses filtering with microporous membrane, obtains Chinese medicine extraction liquid.
9. according to the described method of claim 8, it is characterized in that: described transdermal enhancer is an azone, 1,2-propylene glycol, dimethyl sulfoxide or acetylated monoglyceride; Described oil phase comprises stearic acid, glyceryl monostearate, vaseline or paraffin.
10. any one described Chinese medicine composition of claim 1-3 prevents or treats the purposes in the mammitis of cow medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210292653.2A CN102772520B (en) | 2012-08-16 | 2012-08-16 | Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210292653.2A CN102772520B (en) | 2012-08-16 | 2012-08-16 | Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102772520A true CN102772520A (en) | 2012-11-14 |
| CN102772520B CN102772520B (en) | 2014-06-18 |
Family
ID=47117777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210292653.2A Expired - Fee Related CN102772520B (en) | 2012-08-16 | 2012-08-16 | Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772520B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511999A (en) * | 2016-12-06 | 2017-03-22 | 中国农业科学院兰州畜牧与兽药研究所 | Drug composition used for preventing and treating mastitis and carbuncle swelling of dairy cow as well as preparation method and application of drug composition |
| CN110538221A (en) * | 2019-09-09 | 2019-12-06 | 郑州百瑞动物药业有限公司 | Compound film spraying agent for dairy cows and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660274A (en) * | 2004-12-29 | 2005-08-31 | 李发明 | Combination of lmedication for treatig mastitis of cow and preparation method |
| CN101167936A (en) * | 2007-10-18 | 2008-04-30 | 扬中牧乐药业有限公司 | Natural plant extraction liquid for preventing cow mastitis and preparation method thereof |
-
2012
- 2012-08-16 CN CN201210292653.2A patent/CN102772520B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660274A (en) * | 2004-12-29 | 2005-08-31 | 李发明 | Combination of lmedication for treatig mastitis of cow and preparation method |
| CN101167936A (en) * | 2007-10-18 | 2008-04-30 | 扬中牧乐药业有限公司 | Natural plant extraction liquid for preventing cow mastitis and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511999A (en) * | 2016-12-06 | 2017-03-22 | 中国农业科学院兰州畜牧与兽药研究所 | Drug composition used for preventing and treating mastitis and carbuncle swelling of dairy cow as well as preparation method and application of drug composition |
| CN110538221A (en) * | 2019-09-09 | 2019-12-06 | 郑州百瑞动物药业有限公司 | Compound film spraying agent for dairy cows and preparation method thereof |
| CN110538221B (en) * | 2019-09-09 | 2021-10-19 | 郑州百瑞动物药业有限公司 | Compound film spraying agent for dairy cows and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102772520B (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102894192B (en) | Chinese herbal feed additive for piglet diarrhea prevention and treatment | |
| CN105123816A (en) | Sterilizing and disinfecting liquid for clinical laboratory and preparation method | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN102772520B (en) | Traditional Chinese medicine composition for preventing or treating bovine mastitis and preparation method of composition | |
| CN106267193A (en) | A kind of for infusion of medicine agent treating bovine mastitis and its preparation method and application | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN105613612A (en) | Agent for disinfecting intensive care unit and preparation method | |
| CN104784299B (en) | A kind of fermented tcm composition of kuh-seng containing wolf's milk and radix scutellariae and preparation method thereof | |
| CN103191264A (en) | Traditional Chinese veterinary medicine oral solution for preventing and treating colibacillosis of poultry | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN101366852B (en) | Chinese medicinal herb for treating riemerella anatipestifer disease and preparation method thereof | |
| CN103494913B (en) | Preparation method of compound radix astragali immune activation injection | |
| CN104324301A (en) | Anti-coccidiosis traditional Chinese medicine extract | |
| CN104324302A (en) | Preparation method of anti-coccidiosis traditional Chinese medicine extract | |
| CN115006496B (en) | Chinese herbal medicine composition for treating pneumonia of foxes, raccoon dogs and martens | |
| CN103784600A (en) | Chinese herbal medicine oral solution for enhancing immunity of racoon dog | |
| CN115715783B (en) | Traditional Chinese medicine composition for preventing and treating white diarrhea of pigs and preparation method thereof | |
| CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
| CN109248219A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment brickpox | |
| CN107349376A (en) | A kind of prebiotic medicine of anti-Eimeria species and its preparation method and application | |
| CN1939380B (en) | Heat-clearing analgesic medicinal composition with anti-infective and antiviral functions | |
| CN109223888B (en) | Fae and faeG gene expression traditional Chinese medicine composition for inhibiting enterotoxigenic escherichia coli K88 fimbriae and application | |
| CN103494914B (en) | Compound radix astragali immune activation injection | |
| CN101375931A (en) | Chinese medicine oral liquid with heat-clearing and dampness-draining functions as well as application thereof for livestock and poultry | |
| CN106472354B (en) | A kind of Adult Chicken feed dish |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: WEI CHENGWEI XIAO JIANHUA Effective date: 20150209 Owner name: NORTHEAST AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: GAO LI Effective date: 20150209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Li Inventor after: Wei Chengwei Inventor after: Xiao Jianhua Inventor after: Fan Honggang Inventor after: Li Yanfei Inventor after: Zhang Jiantao Inventor after: Liu Benjun Inventor after: Wang Hongbin Inventor before: Gao Li Inventor before: Wei Chengwei Inventor before: Xiao Jianhua Inventor before: Fan Honggang Inventor before: Li Yanfei Inventor before: Zhang Jiantao Inventor before: Liu Benjun Inventor before: Wang Hongbin |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150209 Address after: 150030 Xiangfang City, Harbin Province Wood Street, No. 59, No. Patentee after: Northeast Agricultural University Address before: 150030 Harbin City, Xiangfang Province, No. 59 Wood Street,, Northeast Agricultural University Patentee before: Gao Li Patentee before: Wei Chengwei Patentee before: Xiao Jianhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 Termination date: 20210816 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |